107 related articles for article (PubMed ID: 2345069)
41. Pharmacological activities of spirogermanium and other structurally related azaspiranes: effects on tumor cell and macrophage functions.
Mirabelli CK; Badger AM; Sung CP; Hillegass L; Sung CM; Johnson RK; Picker D; Schwartz D; Dorman J; Martellucci S
Anticancer Drug Des; 1989 Mar; 3(4):231-42. PubMed ID: 2930625
[TBL] [Abstract][Full Text] [Related]
42. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.
de Jonge M; de Weger VA; Dickson MA; Langenberg M; Le Cesne A; Wagner AJ; Hsu K; Zheng W; Macé S; Tuffal G; Thomas K; Schellens JH
Eur J Cancer; 2017 May; 76():144-151. PubMed ID: 28324749
[TBL] [Abstract][Full Text] [Related]
43. Effect of spirogermanium and radiation therapy on the 9L rat brain tumor model.
Kimler BF; Martin DF; Evans RG; Morantz RA; Vats TS
NCI Monogr; 1988; (6):115-8. PubMed ID: 3352753
[TBL] [Abstract][Full Text] [Related]
44. Preliminary study on the suppression of experimental autoimmune encephalomyelitis in the Lewis rat with spirogermanium.
Sacks HJ; Braunstein V; Brosnan CF
J Neuropathol Exp Neurol; 1987 May; 46(3):250-61. PubMed ID: 3494106
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
[TBL] [Abstract][Full Text] [Related]
46. Phase I trial of piritrexim capsules using prolonged, low-dose oral administration for the treatment of advanced malignancies.
Feun LG; Savaraj N; Benedetto P; Hanlon J; Sridhar KS; Collier M; Richman S; Liao SH; Clendeninn NJ
J Natl Cancer Inst; 1991 Jan; 83(1):51-5. PubMed ID: 1984518
[TBL] [Abstract][Full Text] [Related]
47. Determination of spirogermanium (2-aza-8-germanspiro[4.5]-decane-2-propanamine-8,8-diethyl-N,N-dimethyl dichloride) by fluorometric ion-pair extraction. Application to the uniformity of content of solutions for intravenous injection.
Riley CM; Monnot EA; Stobaugh JF; Slavik M
J Pharm Biomed Anal; 1989; 7(3):385-92. PubMed ID: 2488639
[No Abstract] [Full Text] [Related]
48. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
49. Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors.
Korfel A; Scheulen ME; Schmoll HJ; Gründel O; Harstrick A; Knoche M; Fels LM; Skorzec M; Bach F; Baumgart J; Sass G; Seeber S; Thiel E; Berdel WE
Clin Cancer Res; 1998 Nov; 4(11):2701-8. PubMed ID: 9829732
[TBL] [Abstract][Full Text] [Related]
50. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
Rapoport B; Chua D; Poma A; Arora S; Wang Y; Fein LE
Support Care Cancer; 2015 Nov; 23(11):3281-8. PubMed ID: 25940030
[TBL] [Abstract][Full Text] [Related]
51. Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors.
Dupont J; Bienvenu B; Aghajanian C; Pezzulli S; Sabbatini P; Vongphrachanh P; Chang C; Perkell C; Ng K; Passe S; Breimer L; Zhi J; DeMario M; Spriggs D; Soignet SL
J Clin Oncol; 2004 Aug; 22(16):3366-74. PubMed ID: 15310782
[TBL] [Abstract][Full Text] [Related]
52. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M
Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330
[TBL] [Abstract][Full Text] [Related]
53. Trypanosoma cruzi: inhibition by spirogermanium hydrochloride.
Tanowitz HB; Brennessel DJ; Baum SG; Salgo MP; Braunstein V; Wittner M
Exp Parasitol; 1987 Aug; 64(1):57-63. PubMed ID: 3301388
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
[TBL] [Abstract][Full Text] [Related]
55. Cytotoxic effects and biological activity of 2-aza-8-germanspiro[4,5]-decane-2-propanamine-8,8-diethyl-N,N-dimethyl dichloride (NSC 192965; spirogermanium) in vitro.
Hill BT; Whatley SA; Bellamy AS; Jenkins LY; Whelan RD
Cancer Res; 1982 Jul; 42(7):2852-6. PubMed ID: 7200828
[TBL] [Abstract][Full Text] [Related]
56. Phase I study of mitoxantrone on a daily X 5 schedule.
Goldsmith MA; Ohnuma T; Jaffrey IH; Greenspan EM; Holland JF
Am J Clin Oncol; 1984 Oct; 7(5):567-70. PubMed ID: 6507380
[TBL] [Abstract][Full Text] [Related]
57. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK
Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438
[TBL] [Abstract][Full Text] [Related]
58. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH
Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
[TBL] [Abstract][Full Text] [Related]
59. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
[TBL] [Abstract][Full Text] [Related]
60. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
Dragovich T; Mendelson D; Kurtin S; Richardson K; Von Hoff D; Hoos A
Cancer Chemother Pharmacol; 2006 Dec; 58(6):759-64. PubMed ID: 16847673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
